샘플 요청 목록

 카트 문의
시장보고서
상품코드
1536136

세계 심근경색(MI) 치료 시장

Myocardial Infarction (MI) Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 296 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

심근경색(MI) 치료 세계 시장은 2030년까지 21억 달러에 달할 전망

2023년에 17억 달러로 추정되는 심근경색(MI) 치료 세계 시장은 분석 기간 2023-2030년에 CAGR 3.0%로 성장하고, 2030년에는 21억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 항혈소판제는 CAGR 3.9%로 성장을 지속하고, 분석 기간 종료시에는 9억 5,460만 달러에 달할 것으로 예측됩니다. 당단백질 IIb/IIIa 억제제 분절의 성장률은 분석 기간 동안 CAGR 2.9%로 추정됩니다.

미국 시장은 추정 4억 6,980만 달러, 중국은 CAGR 6.0%로 성장 예측

미국의 심근경색(MI) 치료 시장은 2023년 4억 6,980만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 4억 3,490만 달러 규모에 이를 것으로 예측되며, 분석 기간 2023-2030년의 CAGR은 6.0%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 0.8%와 2.3%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 1.5%로 성장할 것으로 예측됩니다.

세계의 심근경색(MI) 치료 시장- 주요 동향과 촉진요인 정리

일반적으로 심장 발작으로 알려진 심근 경색(MI)은 심장의 일부로의 혈류가 장시간 차단되어 심근의 일부가 손상되거나 사멸될 때 발생합니다. 심근 경색의 가장 흔한 원인은 관상 동맥 벽에 지방이 축적되어 플라그를 형성하는 것입니다. 이 플라크가 파열되면 혈전이 형성되고 혈류가 억제됩니다. 혈류를 회복시키고 심장 손상을 최소화하기 위해서는 조기 치료가 중요합니다. 심근 경색의 주요 치료에는 항혈소판제, 항응고제, 혈전 용해제, 베타 차단제, ACE 억제제 등의 약제가 사용됩니다. 이 약은 혈전을 녹이고 심장 일량을 줄이고 혈전의 추가 형성을 방지하는 데 도움이 됩니다. 약물 요법 외에도 폐색 된 동맥을 재개통시켜 혈류를 회복시키기 위해서는 혈관 성형술, 스텐트 유치술, 관상 동맥 우회술(CABG)과 같은 침습적 치료가 필요합니다. 입니다.

기술의 진보로 심근 경색의 치료 성적이 크게 향상되었습니다. 동맥의 재폐색을 막는 약물을 방출하는 약물 용출 스텐트의 개발은 혈관성형술에 혁명을 일으켰습니다. 또한 혈관 내 초음파(IVUS) 및 광 간섭 단층계(OCT)와 같은 고급 이미징 기술을 사용하여 동맥 폐색을 정확하게 평가하고 더 나은 치료 계획을 수립 할 수 있습니다. 했습니다. 원격 의료 및 원격 모니터링 기술을 통해 의료 서비스 제공업체가 환자의 심장 상태를 더욱 상세하게 모니터링하고 심근 경색의 징후에 신속하게 대응할 수 있게 되었습니다. 또한 운동 훈련, 식사 상담, 심리적 지원 등을 포함한 종합적인 심장 재활 프로그램의 실시는 심근 경색 환자의 장기적인 결과와 QOL 개선에 효과적인 것으로 입증되었습니다.

심근 경색 치료 시장의 성장은 여러 요인에 의해 초래됩니다. 저침습 수술기술과 보다 효과적인 약물요법 개발 등 의료기술의 진보가 시장 확대를 뒷받침하고 있습니다. 또한 고령화와 식생활의 혼란, 운동부족, 흡연 등 라이프스타일 요인에 의한 심혈관질환의 유병률 증가도 심근경색 치료에 대한 수요를 끌어올리고 있습니다. 게다가 공중보건 활동과 교육 캠페인에 의해 지원되는 조기진단·조기개입의 중요성에 대한 의식의 고조가 보다 시기 적절하고 효과적인 치료로 이어지고 있습니다. 유전적, 환경적, 생활습관적 요인에 근거하여 개별 환자 프로파일에 맞춘 치료 계획을 세우는 맞춤형 의료의 대두도 중요한 촉진요인입니다. 지속적인 모니터링과 심장 문제의 조기 발견을 용이하게 하는 웨어러블 건강 기술과 모바일 건강 용도의 혁신은 시장 성장에 더욱 기여하고 있습니다. 또한 첨단 지역의 견고한 건강 관리 인프라와 신흥 국가 시장의 건강 관리 서비스에 대한 접근성 향상이 MI 치료의 밑단을 넓히고 있습니다. 의료 서비스 제공업체가 새로운 기술과 방법을 계속 채택함으로써 심근 경색 치료 시장은 지속적인 성장을 이룰 것으로 예상됩니다.

조사 대상 기업 예(전 86건)

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Amgen, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Bayer AG
  • Biocardia, Inc.
  • Boehringer Ingelheim International GmbH
  • CellProthera
  • CSL Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Faraday Pharmaceuticals
  • Kancera AB
  • Nordic Bioscience A/S
  • Tenaya Therapeutics
  • Viatris Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

JHS 24.08.29

Global Myocardial Infarction (MI) Treatment Market to Reach US$2.1 Billion by 2030

The global market for Myocardial Infarction (MI) Treatment estimated at US$1.7 Billion in the year 2023, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2023-2030. Antiplatelet Agents, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$954.6 Million by the end of the analysis period. Growth in the Glycoprotein IIb / IIIa Inhibitors segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$469.8 Million While China is Forecast to Grow at 6.0% CAGR

The Myocardial Infarction (MI) Treatment market in the U.S. is estimated at US$469.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$434.9 Million by the year 2030 trailing a CAGR of 6.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Myocardial Infarction (MI) Treatment Market - Key Trends and Drivers Summarized

Myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow to a part of the heart is blocked for a long enough time that part of the heart muscle is damaged or dies. The most common cause of MI is the buildup of fatty deposits on the walls of coronary arteries, which form plaques. When these plaques rupture, a blood clot can form and obstruct the blood flow. Immediate treatment is crucial to restore blood flow and minimize heart damage. The primary treatment for MI includes medications such as antiplatelets, anticoagulants, thrombolytics, beta-blockers, and ACE inhibitors. These drugs help dissolve clots, reduce the heart's workload, and prevent further clot formation. In addition to medication, invasive procedures like angioplasty and stent placement, as well as coronary artery bypass grafting (CABG), are often necessary to reopen blocked arteries and restore blood flow.

Advancements in technology have significantly improved the outcomes of MI treatment. The development of drug-eluting stents, which release medication to prevent artery re-blockage, has revolutionized angioplasty procedures. Moreover, the use of advanced imaging techniques such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) allows for precise assessment of arterial blockages and better planning of interventions. Telemedicine and remote monitoring technologies have also made it possible for healthcare providers to monitor patients' heart health more closely and respond quickly to signs of a potential MI. Furthermore, the implementation of comprehensive cardiac rehabilitation programs, which include exercise training, dietary counseling, and psychological support, has proven to be effective in improving the long-term outcomes and quality of life for MI patients.

The growth in the myocardial infarction treatment market is driven by several factors. Advances in medical technology, such as the development of minimally invasive surgical techniques and more effective drug therapies, are propelling market expansion. The increasing prevalence of cardiovascular diseases due to aging populations and lifestyle factors like poor diet, lack of exercise, and smoking is also driving demand for MI treatments. Additionally, heightened awareness about the importance of early diagnosis and intervention, supported by public health initiatives and education campaigns, is leading to more timely and effective treatments. The rise of personalized medicine, which tailors treatment plans to individual patient profiles based on genetic, environmental, and lifestyle factors, is another significant driver. Innovations in wearable health technologies and mobile health applications that facilitate continuous monitoring and early detection of heart issues are further contributing to market growth. Moreover, robust healthcare infrastructure in developed regions and improving access to healthcare services in emerging markets are expanding the reach of MI treatments. As healthcare providers continue to adopt new technologies and methods, the market for myocardial infarction treatments is expected to experience sustained growth.

Select Competitors (Total 86 Featured) -

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Amgen, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Bayer AG
  • Biocardia, Inc.
  • Boehringer Ingelheim International GmbH
  • CellProthera
  • CSL Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Faraday Pharmaceuticals
  • Kancera AB
  • Nordic Bioscience A/S
  • Tenaya Therapeutics
  • Viatris Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Myocardial Infarction (MI) Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Cardiovascular Diseases Expands Addressable Market Opportunity
    • Advances in Minimally Invasive Surgical Techniques Propel Growth
    • Development of Effective Drug Therapies Strengthens Business Case for Treatment Adoption
    • Aging Population and Lifestyle Factors Drive Demand for MI Treatments
    • Heightened Awareness of Early Diagnosis and Intervention Spurs Market Expansion
    • Rise of Personalized Medicine Strengthens Business Case for Customized Treatments
    • Mobile Health Applications Facilitate Continuous Monitoring and Drive Adoption
    • Robust Healthcare Infrastructure in Developed Regions Sustains Growth
    • Improving Access to Healthcare Services in Emerging Markets Expands Reach
    • Technological Advancements in Imaging Techniques Enhance Treatment Precision
    • Increasing Utilization of Telemedicine Throws the Spotlight on Remote Monitoring
    • Enhanced Patient Outcomes with Drug-Eluting Stents Drive Market Adoption
    • Implementation of Artificial Intelligence in Diagnosis and Treatment Planning Spurs Growth
    • Focus on Reducing Healthcare Costs Through Effective MI Management Expands Market Opportunity
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Myocardial Infarction (MI) Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Myocardial Infarction (MI) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Myocardial Infarction (MI) Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antiplatelet Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antiplatelet Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antiplatelet Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Glycoprotein IIb / IIIa Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Glycoprotein IIb / IIIa Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Glycoprotein IIb / IIIa Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Antithrombotic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Antithrombotic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Antithrombotic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Beta-Adrenergic Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Beta-Adrenergic Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Beta-Adrenergic Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Drug Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Drug Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Drug Stores by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • JAPAN
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • CHINA
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • EUROPE
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Myocardial Infarction (MI) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Myocardial Infarction (MI) Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • FRANCE
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • GERMANY
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Myocardial Infarction (MI) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Myocardial Infarction (MI) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • INDIA
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Myocardial Infarction (MI) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Myocardial Infarction (MI) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Myocardial Infarction (MI) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Myocardial Infarction (MI) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • AFRICA
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제